Precigen (PGEN) Income from Continuing Operations (2012 - 2026)
Precigen's (PGEN) quarterly Income from Continuing Operations came in at 7929000.0 in Q1 2026, up 85.36% year-on-year from 4277664.57 in Q1 2025, and up 66.26% on a QoQ basis from 23503000.0 in Q4 2025.
Precigen (PGEN) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Income from Continuing Operations data on file, last reported at 7929000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 85.36% year-over-year to 7929000.0 in Q1 2026; TTM through Mar 2026 was 204418000.0, a 30.49% decrease from a year earlier, with the FY2025 full-year figure at 250642000.0, down 98.55% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 7929000.0, up from 23503000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for PGEN reached as high as 7644000.0 in Q3 2022 and fell as low as 146344000.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 32969823.53 across 5 years, with a median of 23738000.0 in 2024.
- Across the five-year window, Income from Continuing Operations slumped 510.33% in 2025 and soared 85.36% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 22176000.0 in 2022, then sank by 49.06% to 33056000.0 in 2023, then surged by 40.32% to 19727000.0 in 2024, then fell by 19.14% to 23503000.0 in 2025, then soared by 66.26% to 7929000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 7929000.0 in Q1 2026, 23503000.0 in Q4 2025, and 146344000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Precigen | 1.96 Bn | 1.96 Bn | 20.69 Mn | -7.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.93 Mn |
| Dec 31, 2025 | -23.50 Mn |
| Sep 30, 2025 | -146.34 Mn |
| Jun 30, 2025 | -26.64 Mn |
| Mar 31, 2025 | -54.15 Mn |
| Dec 31, 2024 | -19.73 Mn |
| Sep 30, 2024 | -23.98 Mn |
| Jun 30, 2024 | -58.79 Mn |
| Mar 31, 2024 | -23.74 Mn |
| Dec 31, 2023 | -33.06 Mn |
| Sep 30, 2023 | -19.80 Mn |
| Jun 30, 2023 | -20.32 Mn |
| Mar 31, 2023 | -22.73 Mn |
| Dec 31, 2022 | -22.18 Mn |
| Sep 30, 2022 | -7.64 Mn |
| Jun 30, 2022 | -26.06 Mn |
| Mar 31, 2022 | -23.90 Mn |
| Dec 31, 2021 | -26.70 Mn |
| Sep 30, 2021 | -26.32 Mn |
| Jun 30, 2021 | -30.94 Mn |